Evidence map›Paper›PMID 40913206›Full record

ArticleMolecular neurobiology2025

Exosomal miR-494 from Bone Marrow Mesenchymal Stem Cells Attenuates Ferroptosis and Enhances Spinal Cord Injury Repair by Modulating the SIRT1/HO-1 Pathway.

Shengbo Shi, Zijing Zhang, Pengpeng Shi, Changsheng Gong, Zetian Zhao, Tienan Wang, Yu Zhou, Meng Zhang, Junxiao Gao, Song Qin and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. miR-24-3p promotes spinal cord injury repair in rats by inhibiting ferroptosisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shengbo ShiAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Zijing ZhangAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Pengpeng ShiShangqiu First People's Hospital, No. 292 Kaixuan South Road, Suiyang District, Shangqiu City, Henan Province, 476005, People's Republic of China.
Changsheng GongAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Zetian ZhaoAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Tienan WangAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Yu ZhouAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Meng ZhangAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Junxiao GaoAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Song QinAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Jianchuan WangAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China.
Xiaobing YuAffiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Zhongshan District, Dalian, Liaoning Province, 116001, People's Republic of China. yuxiaobing1976@hotmail.com.

Funding

Dalian Science and Technology Innovation Fund 2021JJ13SN68
6 · The paper itself

Abstract

Spinal cord injury (SCI) is a severe traumatic disorder of the central nervous system, often resulting in partial or complete loss of sensory and motor functions. Ferroptosis, a lipid peroxidation-driven apoptotic process triggered by iron overload, has emerged as a novel form of programmed cell death and a focal point in post-SCI cell death research. Exosomes (Exo), as delivery vehicles, exhibit multiple advantages, including superior encapsulation capacity, high targeting efficiency, and enhanced blood-brain barrier penetration to reach the central nervous system. Previous studies have identified exosomes as key carriers of bioactive molecules, including miRNAs. Our prior investigations demonstrated that miR-494 attenuates SCI progression. To investigate the therapeutic mechanism of Exo-miR-494 in SCI, this study conducted in vitro and in vivo experiments using PC12 cell models and rat SCI models. In vitro, qRT-PCR and Western blot were employed to detect the expression levels of miR-494, SIRT1, HO-1, GPX4, and 4HNE, while intracellular oxidative stress markers were measured to clarify the regulatory effects of Exo-miR-494 on cellular oxidative stress and ferroptosis. In vivo, rats with successful SCI modeling were intravenously injected with Exo-miR-494. Fluorescence quantitative PCR, Western blot, and immunofluorescence were comprehensively used to analyze the changes in SIRT1/HO-1 signaling pathway molecules and ferroptosis-related indicators in injured spinal cord tissues. HE staining and Nissl staining were applied to evaluate spinal cord tissue damage and neuronal morphology. Transmission electron microscopy was utilized to observe cellular ultrastructural changes, and Prussian blue staining was combined to detect iron deposition, thereby deeply exploring the ferroptosis mechanism. Finally, Basso, Beattie, Bresnahan (BBB) locomotor scores and inclined plane tests were used to systematically assess the motor function recovery of rats. Results revealed a significant downregulation of miR-494 post-SCI. Exo-miR-494 effectively restored miR-494 levels in injured spinal tissues, suppressed ferroptosis through SIRT1/HO-1 pathway activation, mitigated SCI progression, and enhanced functional recovery in rats. Exosomes derived from rat bone marrow mesenchymal stem cells (BMSCs) delivering miR-494 represent a potential therapeutic strategy for SCI. miR-494 targets injury sites, reduces neuronal ferroptosis after spinal cord injury by regulating the SIRT1/HO-1 signaling pathway, alleviates damage caused by spinal cord injury, and promotes motor function recovery in rats.

Indexed as

ExosomesFerroptosisHeme Oxygenase-1Mesenchymal Stem CellsMicroRNAsSirtuin 1Spinal Cord InjuriesAnimalsMaleOxidative StressPC12 CellsRatsRats, Sprague-DawleyRecovery of FunctionSignal TransductionHeme Oxygenase-1MicroRNAsSirt1 protein, ratSirtuin 1ExosomeFerroptosisMiR-494Neural repairSIRT1/HO-1Spinal cord injury

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.